2023-04-03 09:36:17 ET
- Heron Therapeutics ( NASDAQ: HRTX ) appointed Craig Collard as CEO, effective immediately, succeeding Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board.
- The board elected Adam Morgan as Chairman; currently, he serves as Chief Investment Officer of Velan Capital Investment Management.
- With 30+ years of experience leading innovative pharmaceutical companies through periods of strategic change to deliver growth, Mr. Collard most recenltly served as CEO of Veloxis Pharmaceutics before its acquisition by Asahi Kasei.
For further details see:
Heron Therapeutics picks industry veteran as CEO, elects new board chairman